CellinCells
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CellinCells - overview
Established
2014
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2014, CellinCells develops regenerative therapies by devising the self-structuring ability of cells as a platform technology. The company saw the potential for use of regenerative therapy while researching the self-structuring ability of cells. CellinCells focused on the development of skin regeneration treatments through 3D tissue shape platform technology. In 2016, the company obtained a patent for a structure for tissue regeneration and manufacturing method.
In 2018, CellinCells signed a Research Consignment Contract with Seoul National University Industry-Academic Cooperation Foundation (Seoul National University Hospital Orthopedic Surgery). The company is focused on research and development for its regenerative medicine stem cell therapy technology. CellinCells plans to conduct clinical trials in cooperation with Samsung Seoul Hospital and others.
Current Investors
KB Investment, JX Partners, Ulmus Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Alternative Medicine, Hospitals
Website
www.cellincells.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.